نتایج جستجو برای: cladribine

تعداد نتایج: 689  

2015
Julia Pakpoor Giulio Disanto Daniel R. Altmann Sue Pavitt Benjamin P. Turner Monica Marta Gunnar Juliusson David Baker Jeremy Chataway Klaus Schmierer

OBJECTIVE To compare the cancer risk of cladribine and other disease-modifying drugs (DMDs) in trials of people with relapsing multiple sclerosis (pwRMS). METHODS Meta-analysis of phase III trials of licensed DMDs for pwRMS and a phase III trial of cladribine (CLARITY). Cancer rates were compared using Fisher exact test. RESULTS Eleven trials were included. Investigated treatments included ...

2017
David Baker Samuel S. Herrod Cesar Alvarez-Gonzalez Lukasz Zalewski Christo Albor Klaus Schmierer

OBJECTIVE To understand the efficacy of cladribine (CLAD) treatment in MS through analysis of lymphocyte subsets collected, but not reported, in the pivotal phase III trials of cladribine and alemtuzumab induction therapies. METHODS The regulatory submissions of the CLAD Tablets Treating Multiple Sclerosis Orally (CLARITY) (NCT00213135) cladribine and Comparison of Alemtuzumab and Rebif Effic...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 1999
M J Rummel K U Chow E Jäger D K Hossfeld L Bergmann H D Peters M L Hansmann A Meyer D Hoelzer P S Mitrou

PURPOSE Cladribine (2-chlorodeoxyadenosine, 2-CdA) has been reported to be effective in the treatment of low-grade lymphomas. The objective of this multicenter study was to evaluate the activity of cladribine in mantle-cell lymphomas as first-line therapy or in first relapse using an intermittent two-hour infusion of cladribine. PATIENTS AND METHODS A total of 47 courses, or an average of fou...

2010
Julie A Murphy Jacklyn A Harris Andrew J Crannage

Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system. The clinical course of MS varies among patients. Currently, interferon (IFN) products, including IFN β-1a administered intramuscularly or subcutaneously and IFN β-1b subcutaneously, glatiramer acetate, natalizumab, and mitoxantrone are approved disease-modifying therapies for the treatment of relapsing...

2012
Teri L. Schreiner Augusto Miravalle

Multiple Sclerosis (MS) is a chronic inflammatory, immune-mediated, demyelinating disorder of the central nervous system with a heterogeneous clinical presentation and pathology in which activated lymphocytes play an important role in mediating tissue damage. Until recently, all first line therapies for MS were injectable. Several oral medications have been studied for preventative treatment of...

Journal: :BMC Pharmacology 2005
Synnöve Lindemalm Radojka M Savic Mats O Karlsson Gunnar Juliusson Jan Liliemark Freidoun Albertioni

BACKGROUND The nucleoside analog cladribine is used for the treatment of a variety of indolent B- and T-cell lymphoid malignancies. The primary aim of the study was to evaluate the population distribution of pharmacokinetic parameters in patients undergoing treatment with cladribine and to detect the influence of different covariates on the pharmacokinetic parameters. METHODS This pharmacokin...

جلائی‌خو, حسن, کیهانی, منوچهر, یوسفیان, ابوالفضل,

Normal 0 false false false EN-US X-NONE AR-SA MicrosoftInternetExplorer4 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal" mso-tsty...

2017
Mark S Freedman Thomas P Leist Giancarlo Comi Bruce AC Cree Patricia K Coyle Hans-Peter Hartung Patrick Vermersch Doris Damian Fernando Dangond

BACKGROUND Multiple sclerosis (MS) diagnostic criteria have changed since the ORACLE-MS study was conducted; 223 of 616 patients (36.2%) would have met the diagnosis of MS vs clinically isolated syndrome (CIS) using the newer criteria. OBJECTIVE The objective of this paper is to assess the effect of cladribine tablets in patients with a first clinical demyelinating attack fulfilling newer cri...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 1996
G Juliusson J Liliemark

PURPOSE To assess long-term survival following cladribine salvage treatment for previously treated patients with chronic lymphocytic leukemia. PATIENTS AND METHODS Fifty-two patients aged 39-84 years with previously treated CLL received cladribine 0.12 mg/kg/day in 2-hour infusions for 5 days in monthly courses. Two-thirds were refractory to previous therapy, and 8 had prior fludarabine. RE...

Journal: :Reactions Weekly 2021

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید